Last Price$59.76.8%
Market Cap$3,532.4M
LTM Operating Income
$252.8M
YoY Growth
N/A
3Y CAGR
N/A
5Y CAGR
N/A
Stock quality & Intrinsic value
7/10
65.3% overvalued
Protagonist Therapeutics, Inc. Operating Income
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | ($9,319.0K) | ($14.8M) | ($32.7M) | ($37.9M) | ($42.3M) | ($80.5M) | ($64.5M) | ($125.8M) | ($131.4M) | ($93.7M) | $252.8M |
Overvalued or undervalued?
Check the intrinsic value for PTGX
and see if it's the right time to invest.
Protagonist Therapeutics, Inc. (PTGX) Operating Income comparison analysis
General
LTM Operating Income
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Protagonist Therapeutics, Inc.PTGX
$252.8M
N/A
N/A
N/A
Median Peer Set
($193.9M)
(0.3%)
0.0%
0.2%
Regeneron Pharmaceuticals, Inc.REGN
$4,021.7M
(0.6%)
(23.4%)
12.7%
United Therapeutics CorporationUTHR
$1,377.0M
16.2%
35.3%
N/A
Royalty Pharma plcRPRX
$1,292.9M
(13.4%)
(3.3%)
(13.2%)
BioMarin Pharmaceutical Inc.BMRN
$460.6M
198.6%
N/A
N/A
Alnylam Pharmaceuticals, Inc.ALNY
($176.9M)
(37.3%)
(37.0%)
(28.4%)
Summit Therapeutics Inc.SMMT
($210.9M)
N/A
34.8%
48.1%
Vertex Pharmaceuticals IncorporatedVRTX
($246.8M)
N/A
N/A
N/A
argenx SEARGX
($385.9M)
(3.6%)
N/A
20.9%
BeiGene, Ltd.BGNE
($872.6M)
(32.5%)
(13.6%)
0.5%
BioNTech SEBNTX
($1,421.8M)
N/A
N/A
48.6%
PTGX key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 20.1 0.0% | 30.9 54.1% | 0.2 (99.3%) | 28.6 12,293.1% | 27.4 (4.4%) | 26.6 (2.8%) | 60.0 125.7% | 434.4 624.1% |
| Cost of Goods Sold (COGS) | 0.0 | 0.2 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 2.8 | 1.0 | 0.0 | 0.0 |
% margin | 0.0 0.0% | (0.2) 0.0% | (0.3) 0.0% | 20.1 100.0% | 30.9 100.0% | 0.2 100.0% | 28.6 100.0% | 24.6 89.9% | 25.5 96.1% | 60.0 100.0% | 434.4 100.0% |
| Operating Expenses | 9.3 | 14.8 | 32.7 | 58.0 | 73.2 | 80.8 | 93.1 | 153.2 | 158.0 | 153.7 | 181.6 |
| Research & Development Expenses (R&D) | 7.5 | 11.8 | 25.7 | 46.2 | 59.5 | 65.0 | 74.5 | 126.0 | 126.2 | 120.2 | 138.1 |
| Selling, General & Administrative Expenses (SG&A) | 1.9 | 3.0 | 7.0 | 11.8 | 13.7 | 15.7 | 18.6 | 27.2 | 31.7 | 33.5 | 43.5 |
% margin | (9.3) 0.0% | (14.8) 0.0% | (32.7) 0.0% | (37.9) (188.9%) | (42.3) (136.7%) | (80.5) (34,857.6%) | (64.5) (225.4%) | (125.8) (460.0%) | (131.4) (494.2%) | (93.7) (156.1%) | 252.8 58.2% |
| Interest Income | 0.0 | 0.0 | 0.2 | 0.9 | 2.6 | 2.8 | 0.9 | 0.4 | 4.1 | 14.9 | 26.3 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.6 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax Income | (11.1) | (14.9) | (37.2) | (37.0) | (39.7) | (77.9) | (64.8) | (125.6) | (127.4) | (79.0) | 279.4 |
% effective tax rate | 1.8 (15.8%) | 0.1 (0.4%) | 4.2 (11.2%) | (0.4) 1.1% | (0.8) 2.0% | (0.7) 0.9% | 1.3 (2.0%) | (2.9) 2.3% | (4.0) 3.1% | 0.0 0.0% | 4.2 1.5% |
% margin | (11.1) 0.0% | (14.9) 0.0% | (37.2) 0.0% | (37.0) (184.2%) | (38.9) (125.9%) | (77.2) (33,414.3%) | (66.2) (231.1%) | (122.6) (448.2%) | (123.4) (464.3%) | (79.0) (131.6%) | 275.2 63.3% |
| EPS | (1.88) | (2.52) | (5.72) | (2.09) | (1.74) | (2.98) | (1.92) | (2.65) | (2.52) | (1.39) | 4.47 |
| Diluted EPS | (1.88) | (2.52) | (5.72) | (2.09) | (1.74) | (2.98) | (1.92) | (2.65) | (2.52) | (1.39) | 4.23 |
% margin | (9.1) 0.0% | (14.5) 0.0% | (32.3) 0.0% | (36.6) (182.2%) | (39.2) (126.7%) | (78.3) (33,898.7%) | (63.7) (222.4%) | (123.1) (449.9%) | (131.4) (494.2%) | (90.3) (150.6%) | 252.8 58.2% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Protagonist Therapeutics, Inc.'s Operating Income?
As of today, Protagonist Therapeutics, Inc.'s last 12-month Operating Income is $252.8M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Protagonist Therapeutics, Inc.'s Operating Income growth rate?
Over the last year, Protagonist Therapeutics, Inc.'s Operating Income growth was N/A. The average annual Operating Income growth rates for Protagonist Therapeutics, Inc. have been N/A over the past three years, N/A over the past five years.